Evidence map›Paper›PMID 34010496›Full record

ReviewChemical record (New York, N.Y.)2021

The Road to Structurally Defined β-Glucans.

Patrick Ross, Mark P Farrell

Open access · greenAbstract readReview
In one paragraph

Review in Chemical record (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Patrick RossDepartment of Medicinal Chemistry, The University of Kansas, 2034 Becker Drive, Lawrence, KS 66047, USA.
Mark P FarrellDepartment of Medicinal Chemistry, The University of Kansas, 2034 Becker Drive, Lawrence, KS 66047, USA.ORCID http://orcid.org/0000-0002-6866-428X
University of Kansas · US

Funding

Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI OROZCO, ROBIN C. · 2016 to 2025
$23.9M
Protein Structure Laboratory P30GM110761 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI HANZLIK, ROBERT P · 2014 to 2018
$5.6M
TRAINING GRANT IN DYNAMIC ASPECTS OF CHEMICAL BIOLOGYT32GM008545 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI LAMB, AUDREY L · 1994 to 2019
$4.9M
NIGMS NIH HHS P20 GM113117NIGMS NIH HHS P30 GM110761NIGMS NIH HHS T32 GM008545
6 · The paper itself

Abstract

β-glucans are polymers of glucose that have been isolated from a variety of organisms. Isolated β-glucans have been used for medical purposes for centuries; however, efforts to define the biological activities of β-glucans experimentally were initiated in the 1940's. The diversity of structure associated with isolated β-glucans has impeded said investigations, and efforts to leverage the biological activity of β-glucans for clinical applications. In recognition of the need for defined β-glucans that retain the biological activity of isolated β-glucans, considerable investment has been made to facilitate the synthesis of structurally defined β-glucans. Here, we review the different approaches that have been applied to prepare β-glucans. In addition, we summarize the approaches that have been utilized to conjugate β-glucans to proteins.

Indexed as

beta-GlucansPolymersbeta-GlucansPolymerscarbohydrate chemistryglycomimeticspolysaccharidesβ-glucans

Identifiers

PMID34010496
PMCPMC9109639
OpenAlexW3163464386

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.